Logo image of IBEX

IBEX LTD (IBEX) Stock Fundamental Analysis

USA - NASDAQ:IBEX - BMG4690M1010 - Common Stock

36.23 USD
-0.29 (-0.79%)
Last: 10/17/2025, 8:19:22 PM
36.23 USD
0 (0%)
After Hours: 10/17/2025, 8:19:22 PM
Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to IBEX. IBEX was compared to 86 industry peers in the IT Services industry. IBEX gets an excellent profitability rating and is at the same time showing great financial health properties. IBEX has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! With these ratings, IBEX could be worth investigating further for value and growth and quality investing!.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

IBEX had positive earnings in the past year.
In the past year IBEX had a positive cash flow from operations.
In the past 5 years IBEX has always been profitable.
IBEX had a positive operating cash flow in each of the past 5 years.
IBEX Yearly Net Income VS EBIT VS OCF VS FCFIBEX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M

1.2 Ratios

The Return On Assets of IBEX (13.49%) is better than 93.02% of its industry peers.
The Return On Equity of IBEX (27.45%) is better than 91.86% of its industry peers.
IBEX has a Return On Invested Capital of 20.43%. This is amongst the best in the industry. IBEX outperforms 93.02% of its industry peers.
Industry RankSector Rank
ROA 13.49%
ROE 27.45%
ROIC 20.43%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBEX Yearly ROA, ROE, ROICIBEX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100

1.3 Margins

IBEX has a better Profit Margin (6.60%) than 69.77% of its industry peers.
In the last couple of years the Profit Margin of IBEX has grown nicely.
Looking at the Operating Margin, with a value of 8.71%, IBEX is in the better half of the industry, outperforming 63.95% of the companies in the same industry.
IBEX's Operating Margin has improved in the last couple of years.
IBEX has a Gross Margin (30.91%) which is comparable to the rest of the industry.
IBEX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 8.71%
PM (TTM) 6.6%
GM 30.91%
OM growth 3Y27.75%
OM growth 5Y12.6%
PM growth 3Y14.82%
PM growth 5Y27.95%
GM growth 3Y0.55%
GM growth 5YN/A
IBEX Yearly Profit, Operating, Gross MarginsIBEX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

7

2. Health

2.1 Basic Checks

IBEX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
IBEX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IBEX Yearly Shares OutstandingIBEX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
IBEX Yearly Total Debt VS Total AssetsIBEX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 5.14 indicates that IBEX is not in any danger for bankruptcy at the moment.
IBEX's Altman-Z score of 5.14 is fine compared to the rest of the industry. IBEX outperforms 73.26% of its industry peers.
The Debt to FCF ratio of IBEX is 0.06, which is an excellent value as it means it would take IBEX, only 0.06 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of IBEX (0.06) is better than 94.19% of its industry peers.
IBEX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of IBEX (0.01) is better than 82.56% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.06
Altman-Z 5.14
ROIC/WACC2.2
WACC9.29%
IBEX Yearly LT Debt VS Equity VS FCFIBEX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 1.82 indicates that IBEX should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.82, IBEX is in line with its industry, outperforming 55.81% of the companies in the same industry.
IBEX has a Quick Ratio of 1.82. This is a normal value and indicates that IBEX is financially healthy and should not expect problems in meeting its short term obligations.
IBEX has a Quick ratio of 1.82. This is comparable to the rest of the industry: IBEX outperforms 58.14% of its industry peers.
Industry RankSector Rank
Current Ratio 1.82
Quick Ratio 1.82
IBEX Yearly Current Assets VS Current LiabilitesIBEX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 32.08% over the past year.
IBEX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 41.04% yearly.
The Revenue has grown by 9.78% in the past year. This is quite good.
IBEX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.62% yearly.
EPS 1Y (TTM)32.08%
EPS 3Y28.16%
EPS 5Y41.04%
EPS Q2Q%50%
Revenue 1Y (TTM)9.78%
Revenue growth 3Y4.24%
Revenue growth 5Y6.62%
Sales Q2Q%18.15%

3.2 Future

Based on estimates for the next years, IBEX will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.11% on average per year.
Based on estimates for the next years, IBEX will show a quite strong growth in Revenue. The Revenue will grow by 8.28% on average per year.
EPS Next Y16.57%
EPS Next 2Y12.11%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year10.8%
Revenue Next 2Y8.28%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IBEX Yearly Revenue VS EstimatesIBEX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
IBEX Yearly EPS VS EstimatesIBEX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3

8

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 12.94 indicates a correct valuation of IBEX.
Compared to the rest of the industry, the Price/Earnings ratio of IBEX indicates a rather cheap valuation: IBEX is cheaper than 81.40% of the companies listed in the same industry.
IBEX is valuated cheaply when we compare the Price/Earnings ratio to 27.42, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 11.10, the valuation of IBEX can be described as very reasonable.
82.56% of the companies in the same industry are more expensive than IBEX, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.94. IBEX is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 12.94
Fwd PE 11.1
IBEX Price Earnings VS Forward Price EarningsIBEX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

86.05% of the companies in the same industry are more expensive than IBEX, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, IBEX is valued a bit cheaper than the industry average as 68.60% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 17.68
EV/EBITDA 7.12
IBEX Per share dataIBEX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

IBEX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of IBEX may justify a higher PE ratio.
IBEX's earnings are expected to grow with 12.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.78
PEG (5Y)0.32
EPS Next 2Y12.11%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

IBEX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

IBEX LTD

NASDAQ:IBEX (10/17/2025, 8:19:22 PM)

After market: 36.23 0 (0%)

36.23

-0.29 (-0.79%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)09-11 2025-09-11/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners94.9%
Inst Owner Change0.22%
Ins Owners8.95%
Ins Owner Change-3.95%
Market Cap482.58M
Analysts45.71
Price Target39.27 (8.39%)
Short Float %1.42%
Short Ratio1.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.37%
Min EPS beat(2)10.89%
Max EPS beat(2)21.85%
EPS beat(4)4
Avg EPS beat(4)13.65%
Min EPS beat(4)7.33%
Max EPS beat(4)21.85%
EPS beat(8)7
Avg EPS beat(8)11.1%
EPS beat(12)10
Avg EPS beat(12)14.9%
EPS beat(16)11
Avg EPS beat(16)6.92%
Revenue beat(2)2
Avg Revenue beat(2)6.82%
Min Revenue beat(2)5.12%
Max Revenue beat(2)8.52%
Revenue beat(4)4
Avg Revenue beat(4)4.42%
Min Revenue beat(4)1.58%
Max Revenue beat(4)8.52%
Revenue beat(8)4
Avg Revenue beat(8)1.31%
Revenue beat(12)4
Avg Revenue beat(12)-0.58%
Revenue beat(16)6
Avg Revenue beat(16)-0.56%
PT rev (1m)0%
PT rev (3m)26.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.55%
EPS NY rev (1m)4.4%
EPS NY rev (3m)4.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)5.66%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.72%
Valuation
Industry RankSector Rank
PE 12.94
Fwd PE 11.1
P/S 0.86
P/FCF 17.68
P/OCF 10.57
P/B 3.59
P/tB 3.95
EV/EBITDA 7.12
EPS(TTM)2.8
EY7.73%
EPS(NY)3.26
Fwd EY9.01%
FCF(TTM)2.05
FCFY5.66%
OCF(TTM)3.43
OCFY9.46%
SpS41.91
BVpS10.08
TBVpS9.16
PEG (NY)0.78
PEG (5Y)0.32
Profitability
Industry RankSector Rank
ROA 13.49%
ROE 27.45%
ROCE 25.17%
ROIC 20.43%
ROICexc 22.19%
ROICexgc 23.83%
OM 8.71%
PM (TTM) 6.6%
GM 30.91%
FCFM 4.89%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y27.75%
OM growth 5Y12.6%
PM growth 3Y14.82%
PM growth 5Y27.95%
GM growth 3Y0.55%
GM growth 5YN/A
F-Score8
Asset Turnover2.04
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.06
Debt/EBITDA 0.01
Cap/Depr 106.63%
Cap/Sales 3.29%
Interest Coverage 29.77
Cash Conversion 69.33%
Profit Quality 74.04%
Current Ratio 1.82
Quick Ratio 1.82
Altman-Z 5.14
F-Score8
WACC9.29%
ROIC/WACC2.2
Cap/Depr(3y)83.97%
Cap/Depr(5y)108.52%
Cap/Sales(3y)2.89%
Cap/Sales(5y)3.72%
Profit Quality(3y)75.63%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.08%
EPS 3Y28.16%
EPS 5Y41.04%
EPS Q2Q%50%
EPS Next Y16.57%
EPS Next 2Y12.11%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)9.78%
Revenue growth 3Y4.24%
Revenue growth 5Y6.62%
Sales Q2Q%18.15%
Revenue Next Year10.8%
Revenue Next 2Y8.28%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.91%
EBIT growth 3Y33.16%
EBIT growth 5Y20.06%
EBIT Next Year66.44%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.92%
FCF growth 3Y24.66%
FCF growth 5Y-10.09%
OCF growth 1Y27.21%
OCF growth 3Y4.51%
OCF growth 5Y-2.46%